Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT01941173

Short-Infusion Ziv-aflibercept in Treating Patients With Metastatic Colorectal Cancer Receiving Combination Chemotherapy

A Prospective Study of Short Infusion of Ziv-Aflibercept in Combination With FOLFIRI in Patients With Metastatic Colorectal Cancer

Status
Withdrawn
Phase
N/A
Study type
Interventional
Enrollment
0 (actual)
Sponsor
City of Hope Medical Center · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This pilot clinical trial studies short-infusion ziv-aflibercept in treating patients with metastatic colorectal cancer receiving combination chemotherapy. Ziv-aflibercept may stop the growth of colorectal cancer by blocking blood flow to the tumor. Giving the drug over a shorter infusion time may result in improved efficiency and patient satisfaction.

Detailed description

PRIMARY OBJECTIVES: I. To determine the feasibility of a shorter infusion of 30 minutes and 15 minutes of standard dose ziv-aflibercept when combined with FOLFIRI (folinic acid \[leucovorin calcium\], fluorouracil, and irinotecan \[irinotecan hydrochloride\]) in patients with metastatic colorectal cancer. SECONDARY OBJECTIVES: I. Describe the institutional safety experience with this combination using Common Terminology Criteria for Adverse Events (CTCAE) version 4 for toxicity grading. OUTLINE: Patients receive ziv-aflibercept intravenously (IV) over 15-30 minutes followed by FOLFIFRI chemotherapy comprising leucovorin calcium IV over 2 hours, irinotecan hydrochloride IV over 90 minutes, and fluorouracil IV over 46 hours on day 1. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up for 30 days.

Conditions

Interventions

TypeNameDescription
BIOLOGICALziv-afliberceptGiven IV
DRUGleucovorin calciumGiven IV
DRUGirinotecan hydrochlorideGiven IV
DRUGfluorouracilGiven IV

Timeline

Start date
2014-01-01
Primary completion
2014-07-01
First posted
2013-09-13
Last updated
2014-07-21

Locations

3 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT01941173. Inclusion in this directory is not an endorsement.